Janux Therapeutics (JANX) Net Income towards Common Stockholders (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$52.9 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 65.83% year-over-year to -$52.9 million in Q1 2026; TTM through Mar 2026 was -$348.5 million, a 56.94% increase from a year earlier, with the FY2025 full-year figure at -$143.2 million, up 66.74% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$52.9 million, down from -$31.9 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for JANX reached as high as -$11.8 million in Q4 2023 and fell as low as -$341.5 million in Q3 2024.
• Historically, Net Income towards Common Stockholders has averaged -$102.8 million across 5 years, with a median of -$54.4 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders slumped 2020.58% in 2022 and jumped 65.83% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$16.4 million in 2022, then increased by 28.34% to -$11.8 million in 2023, then plunged by 71.93% to -$20.2 million in 2024, then plunged by 58.02% to -$31.9 million in 2025, then slumped by 65.47% to -$52.9 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$52.9 million in Q1 2026, -$31.9 million in Q4 2025, and -$131.2 million in Q3 2025.